Expert Guidelines on Dextromethorphan-Bupropion

November 14, 2026by Chris Aiken, MD0
An industry-funded expert panel offers clear advice on switching, combining, and drug interactions with Auvelity.

STUDY: Clayton AH et al, Curr Med Res Opin 2026;42(6):1243–1256

STUDY TYPE: Expert consensus (modified Delphi panel)

FUNDING: Axsome (Auvelity manufacturer). All 10 panelists had financial ties to Axsome, which also funded the medical writing.

Background

Dextromethorphan-bupropion (Auvelity) combines a rapid acting glutamatergic medication (dextromethorphan) with a standard antidepressant (bupropion). Bupropion also extends dextromethorphan’s serum levels by blocking the liver enzyme CYP2D6. That same CYP2D6 blockade makes switching and combining tricky, since many antidepressants and antipsychotics rely on the enzyme. In this paper, experts weigh in on how to make the switch.

The Study
  • Ten US clinicians, including psychiatrists, primary care providers, nurse practitioners, and pharmacists, drafted and voted on recommendations in two virtual meetings in 2024.
  • Consensus required a mean score of at least 3.0 on a 0-to-4 agreement scale, with at least 7 of 10 panelists agreeing.
  • Axsome attended the meetings to answer technical questions and to keep advice consistent with the label.
Results

The panel agreed on 27 recommendations. Eight were unanimous.

Starting the drug:

  • Give one tablet (45 mg/105 mg) daily for three days, then one tablet twice daily.
  • Use measurement-based care to monitor response.
  • Expect dizziness (16% versus 6% on placebo) and nausea (13% versus 9%).
  • Stop the drug in pregnancy or when a patient is trying to conceive.
  • Don’t let patients mix over-the-counter, liquid dextromethorphan with bupropion, as small changes in dextromethorphan can raise blood levels out of proportion.

That last piece of advice is suspect, and may reflect an industry bias toward the branded drug. While it may be true for over-the-counter dextromethorphan (available as a liquid), it doesn’t make sense for prescription-grade, generic pills. Also, people vary in how much bupropion inhibits 2D6, and how active that enzyme is to begin with, so if the worry is about unpredictable dextromethorpan serum levels we should not Auvelity at all.

Still, I agree that prescription pills are preferable to the liquid OTC, as this drug does have a misuse liability.

Switching from an SSRI or SNRI depends on how strongly it blocks CYP2D6:

  • Weak blockers (escitalopram, citalopram, sertraline, venlafaxine, desvenlafaxine): cross-taper, with a slower climb to the full dextromethorphan-bupropion dose.
  • Moderate blockers (duloxetine): reduce to a mid-range dose, then cross-taper.
  • Strong blockers (fluoxetine, paroxetine): stop and wash out for 2 to 3 half-lives before starting.

Other switches:

  • Tricyclics: stop and wash out for 2 to 3 half-lives.
  • MAOIs: stop and wait 14 days. Combining them is contraindicated.
  • Ketamine or esketamine: start the next day or 3 to 4 days later. Agreement was only moderate, and the evidence is a three-patient case series.

Adding it to other treatments:

  • It may be added at full dose to escitalopram, citalopram, sertraline, venlafaxine, desvenlafaxine, vortioxetine, vilazodone, or mirtazapine. Bupropion raises venlafaxine and vortioxetine levels.
  • With duloxetine, lower the dose to 20 to 30 mg a day or give only one tablet of dextromethorphan-bupropion daily.
  • Never add it to bupropion (this would increase the bupropion dose, raising seizure risk).
  • Avoid adding it to tricyclics, especially at higher doses, in patients over 45, or in those with heart disease.
  • With aripiprazole, brexpiprazole, cariprazine, or risperidone, you may need to lower the antipsychotic dose.

The panel also called the drug a first-line option, including for depression with anxiety. The anxiety support comes from a post hoc analysis of an open-label study, where 51.1% reached remission on the Anxiety scale (HAM-A) by week 4.

Practice Implications
  1. The guidance on drug interactions is sound, but some of the advice here is industry biased.
  2. For example, placing dextromethorphan-bupropion first line rests on one positive phase 3 trial and a supporting phase 2 trial that FDA reviewers judged negative under standard analysis (although the trial was published as positive under the industry’s analysis. The anti-anxiety claim rests on open-label data with no control group.
  3. Tolerance and dependence on medications is a top concern for patients, and elevating a medication first-line despite limited data and an abuse liability is questionable.

—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report

What’s Your Take? Share in Comments

Leave a Reply

Your email address will not be published. Required fields are marked *